Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | SVP Finance; Interim CFO & PAO | August 31, 2023 | September 01, 2023 |
| Rezolute, Inc.RZLT · Entity 1990 | VP Finance & CAO | March 04, 2019 | March 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date August 31, 2023 · Filed September 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series Y Preferred StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 1
1 source rowRow 1 · 2023-08-31 · Disposition to issuer · Disposed 6.5 · Balance 0 F1: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company F2: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company
F2: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated.
Rezolute, Inc.
Report date March 04, 2019 · Filed March 07, 2019
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2023 Filed Sep 1, 2023 20:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerSeries Y Preferred Stock | 6.5 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-042369 · form4.xml · nonDerivative · entry 1 Miller Seline E. · CIK 0001769866 · SVP Finance; Interim CFO & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company F2 · shares: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. F2 · price: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 21:19 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 3,250 | $0.47 | $1,527.50 |
DisclosureSEC source: 0001209191-22-045254 · doc4.xml · nonDerivative · entry 1 Miller Seline E. · CIK 0001769866 · SVP Finance; Interim CFO & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2022. Read SEC document |
| February 11, 2022 Filed Feb 23, 2022 21:08 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 107,500 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-22-012159 · doc4.xml · derivative · entry 1 Miller Seline E. · CIK 0001769866 · SVP Finance; Interim CFO & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,500 Underlying: Common Stock · 107,500 shares Expires 2032-02-11 F1 · derivative.exercise_date: 1/4 of the shares subject to the option will vest on the one-year anniversary of the vesting commencement date of February 11, 2022, and 1/48 of the shares subject to the option will vest on each monthly anniversary of the vesting commencement date thereafter. Read SEC document |
| February 09, 2022 Filed Feb 17, 2022 01:10 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 3,250 | $0.46 | $1,495.00 |
DisclosureSEC source: 0001209191-22-010403 · doc4.xml · nonDerivative · entry 1 Miller Seline E. · CIK 0001769866 · SVP Finance; Interim CFO & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,250 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on February 9, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.